Allergan PLC (AGN)

• Annual Data
• Quarterly Data

Allergan PLC, common-size consolidated balance sheet: liabilities and stockholders’ equity

		Dec 31, 2018		Dec 31, 2017		Dec 31, 2016		Dec 31, 2015		Dec 31, 2014
	Accrued third-party rebates
	Accrued payroll and related benefits
	Accrued returns and other allowances
	Accrued R&D expenditures
	Interest payable
	Royalties payable
	Accrued pharmaceutical fees
	Litigation-related reserves and legal fees
	Accrued severance, retention and other shutdown costs
	Accrued non-provision taxes
	Accrued selling and marketing expenditures
	Current portion of contingent consideration obligations
	Contractual commitments, including amount due to Teva
	Dividends payable
	Other accrued expenses
	Accrued expenses
	Accounts payable
	Accounts payable and accrued expenses
	Income taxes payable
	Current portion of long-term debt and capital leases
	Deferred revenue
	Current liabilities held for sale
	Deferred tax liabilities
	Current liabilities
	Long-term debt and capital leases, excluding current portion
	Acquisition related contingent consideration liabilities
	Long-term pension and post retirement liability
	Legacy Allergan deferred executive compensation
	Accrued R&D milestone
	Long-term contractual obligations
	Deferred revenue
	Product warranties
	Long-term severance and restructuring liabilities
	Litigation-related reserves
	Other long-term liabilities
	Other long-term liabilities
	Long-term liabilities held for sale
	Other taxes payable
	Deferred tax liabilities
	Long-term liabilities
	Total liabilities
	Preferred shares, $0.0001 par value per share
	Ordinary shares; $0.0001 par value per share
	Additional paid-in capital
	Retained earnings (accumulated deficit)
	Accumulated other comprehensive income (loss)
	Shareholders’ equity
	Noncontrolling interest
	Total equity
	Total liabilities and equity

Based on: 10-K (filing date: 2019-02-15), 10-K (filing date: 2018-02-16), 10-K (filing date: 2017-02-24), 10-K (filing date: 2016-02-26), 10-K (filing date: 2015-02-18).